Story perspectives
NHS Pricing Talks Collapse, AstraZeneca's £650m Investment at Risk
10/7/2025
35 4
1 of 1
Story summary
- Health Secretary Wes Streeting ended talks with drugmakers on NHS pricing; Lord Vallance leads discussions.
- AstraZeneca's UK investment faces hindrance from an outdated NICE evaluation system, unchanged since 1999.
- Mr. Grady says the UK lacks competitive incentives versus Ireland and Singapore.
- AstraZeneca's £650m package is at risk amid pricing issues; rebates for 2025 rise to nearly 23%.
